J Korean Assoc Oral Maxillofac Surg.  2017 Aug;43(4):272-275. 10.5125/jkaoms.2017.43.4.272.

A case of bisphosphonate-related osteonecrosis of the jaw with a particularly unfavourable course: a case report

• Viviano M
• Addamo A
• Cocca S

• KMID: 2391359
• DOI: http://doi.org/10.5125/jkaoms.2017.43.4.272

Abstract

Bisphosphonates are drugs used to treat osteoclast-mediated bone resorption, including osteoporosis, Paget disease, multiple myeloma, cancer-related osteolysis, and malignant hypercalcemia. The use of these drugs has increased in recent years as have their complications, especially bisphosphonate-related osteonecrosis of the jaw (BRONJ), which more frequently affects the mandible. Here we report a case of BRONJ with a particularly unfavorable course due to cervical inflammation that developed into necrotizing fasciitis, followed by multiorgan involvement leading to septic shock and death.

Keyword

Bisphosphonate-associated osteonecrosis of the jaw; Sepsis; Necrotizing fasciitis; Jaw fractures

MeSH Terms

Bisphosphonate-Associated Osteonecrosis of the Jaw*
Bone Resorption
Diphosphonates
Fasciitis, Necrotizing
Hypercalcemia
Inflammation
Jaw Fractures
Mandible
Multiple Myeloma
Osteolysis
Osteoporosis
Sepsis
Shock, Septic
Diphosphonates

Reference

1. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996; 335:1016–1021. PMID: 8793925.

2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61:1115–1117. PMID: 12966493.

3. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63:1567–1575. PMID: 16243172.

4. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144:753–761. PMID: 16702591.

5. Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum S, et al. Bisphosphonate-related osteonecrosis of the jaws: characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg. 2012; 40:303–309. PMID: 21676622.

6. Lee SH, Chan RC, Chang SS, Tan YL, Chang KH, Lee MC, et al. Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies. Support Care Cancer. 2014; 22:553–560. PMID: 24203085.

7. Ruggiero SL, Woo SB. Biophosphonate-related osteonecrosis of the jaws. Dent Clin North Am. 2008; 52:111–128. ixPMID: 18154867.

8. Tsitsilonis S, Druschel C, Wichlas F, Haas NP, Schwabe P, Bail HJ, et al. Necrotizing fasciitis: is the bacterial spectrum changing? Langenbecks Arch Surg. 2013; 398:153–159. PMID: 22833058.

9. Greinwald JH Jr, Wilson JF, Haggerty PG. Peritonsillar abscess: an unlikely cause of necrotizing fasciitis. Ann Otol Rhinol Laryngol. 1995; 104:133–137. PMID: 7857015.

10. Tung-Yiu W, Jehn-Shyun H, Ching-Hung C, Hung-An C. Cervical necrotizing fasciitis of odontogenic origin: a report of 11 cases. J Oral Maxillofac Surg. 2000; 58:1347–1352. PMID: 11117681.

11. Lorenzini G, Picciotti M, Di Vece L, Pepponi E, Brindisi L, Vessio V, et al. Cervical necrotizing fasciitis of odontogenic origin involving the temporal region--a case report. J Craniomaxillofac Surg. 2011; 39:570–573. PMID: 22036666.

12. Roberson JB, Harper JL, Jauch EC. Mortality associated with cervicofacial necrotizing fasciitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996; 82:264–267. PMID: 8884823.

13. Kaehling Ch, Streckbein P, Schmermund D, Henrich M, Burchert D, Gattenloehner S, et al. Lethal cervical abscess following bisphosphonate related osteonecrosis of the jaw. J Craniomaxillofac Surg. 2014; 42:1203–1206. PMID: 24680164.